Analysts predict that Alkermes Plc (NASDAQ:ALKS) will post earnings of $0.21 per share for the current quarter, Zacks Investment Research reports. Three analysts have provided estimates for Alkermes’ earnings. The highest EPS estimate is $0.35 and the lowest is $0.11. Alkermes posted earnings per share of $0.15 during the same quarter last year, which would indicate a positive year over year growth rate of 40%. The company is expected to announce its next earnings results on Wednesday, February 21st.
On average, analysts expect that Alkermes will report full year earnings of $0.04 per share for the current fiscal year, with EPS estimates ranging from ($0.12) to $0.20. For the next financial year, analysts anticipate that the firm will post earnings of $0.37 per share, with EPS estimates ranging from ($0.24) to $0.96. Zacks’ EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Alkermes.
A number of brokerages have recently commented on ALKS. Zacks Investment Research upgraded Alkermes from a “hold” rating to a “buy” rating and set a $71.00 price target on the stock in a report on Monday. BidaskClub lowered Alkermes from a “hold” rating to a “sell” rating in a report on Saturday, January 20th. Barclays lowered Alkermes from an “overweight” rating to an “equal weight” rating and dropped their price objective for the company from $66.00 to $50.00 in a research note on Monday, October 16th. JPMorgan Chase & Co. set a $78.00 price objective on Alkermes and gave the company a “buy” rating in a research note on Friday, October 27th. Finally, ValuEngine raised Alkermes from a “sell” rating to a “hold” rating in a research report on Friday, December 1st. Eight investment analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. The company has a consensus rating of “Hold” and an average price target of $64.17.
A number of institutional investors have recently bought and sold shares of ALKS. Janus Henderson Group PLC lifted its stake in Alkermes by 13,784.0% in the second quarter. Janus Henderson Group PLC now owns 2,330,992 shares of the company’s stock worth $135,128,000 after purchasing an additional 2,314,203 shares during the last quarter. Thornburg Investment Management Inc. raised its stake in Alkermes by 39.8% in the third quarter. Thornburg Investment Management Inc. now owns 2,779,364 shares of the company’s stock worth $141,303,000 after buying an additional 790,692 shares in the last quarter. Asset Management One Co. Ltd. raised its stake in Alkermes by 6,353.1% in the third quarter. Asset Management One Co. Ltd. now owns 234,377 shares of the company’s stock worth $11,924,000 after buying an additional 230,745 shares in the last quarter. Los Angeles Capital Management & Equity Research Inc. raised its stake in Alkermes by 206.3% in the third quarter. Los Angeles Capital Management & Equity Research Inc. now owns 261,977 shares of the company’s stock worth $13,319,000 after buying an additional 176,442 shares in the last quarter. Finally, AXA bought a new position in Alkermes in the third quarter worth about $8,487,000. 99.31% of the stock is owned by institutional investors and hedge funds.
Shares of Alkermes (ALKS) opened at $55.69 on Tuesday. Alkermes has a 52 week low of $46.42 and a 52 week high of $64.04. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.72 and a current ratio of 3.05. The company has a market capitalization of $8,560.00, a price-to-earnings ratio of -50.17 and a beta of 1.94.
TRADEMARK VIOLATION WARNING: “$0.21 EPS Expected for Alkermes Plc (ALKS) This Quarter” was first published by American Banking News and is the sole property of of American Banking News. If you are reading this news story on another publication, it was copied illegally and reposted in violation of United States & international copyright and trademark laws. The legal version of this news story can be viewed at https://www.americanbankingnews.com/2018/02/06/0-21-eps-expected-for-alkermes-plc-alks-this-quarter.html.
Alkermes Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Alkermes Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes and related companies with MarketBeat.com's FREE daily email newsletter.